Inovio Pharmaceuticals, Inc. Logo

Inovio Pharmaceuticals, Inc.

GBMB.F

(1.8)
Stock Price

0,55 EUR

-79.04% ROA

-86.6% ROE

-1.18x PER

Market Cap.

13.773.576,51 EUR

25.74% DER

0% Yield

-16239.85% NPM

Inovio Pharmaceuticals, Inc. Stock Analysis

Inovio Pharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Inovio Pharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's low PBV ratio (0.63x) suggests it's undervalued, making it an attractive opportunity for investors.

2 DER

The stock has a low debt to equity ratio (18%), which means it has a small amount of debt compared to the ownership it holds

3 Revenue Growth

With a track record of continuous revenue growth in the last three years, this company offers a promising investment opportunity

4 Net Profit Growth

With continuous net profit growth in the past three years, this company demonstrates a strong financial performance, making it an enticing investment opportunity.

5 Graham Number

The company's Graham number indicates that it is undervalued compared to its stock price, suggesting a potentially favorable investment opportunity.

6 ROE

The stock's ROE indicates a negative return (-78.56%) on shareholders' equity, suggesting poor financial performance.

7 ROA

The stock's ROA (-75.69%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock appears overvalued (0) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Inovio Pharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Inovio Pharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Inovio Pharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Inovio Pharmaceuticals, Inc. Revenue
Year Revenue Growth
1998 8.300.000
1999 5.077.339 -63.47%
2001 0 0%
2002 189.521 100%
2003 80.529 -135.35%
2004 1.167.099 93.1%
2005 5.467.253 78.65%
2006 3.468.178 -57.64%
2007 4.807.729 27.86%
2008 2.097.632 -129.2%
2009 9.120.111 77%
2010 6.144.705 -48.42%
2011 9.795.257 37.27%
2012 4.118.652 -137.83%
2013 13.467.346 69.42%
2014 10.456.766 -28.79%
2015 40.572.111 74.23%
2016 35.368.361 -14.71%
2017 42.220.086 16.23%
2018 30.481.897 -38.51%
2019 4.111.930 -641.3%
2020 7.411.220 44.52%
2021 1.774.758 -317.59%
2022 10.262.268 82.71%
2023 410.604 -2399.31%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Inovio Pharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1998 8.100.000
1999 6.977.220 -16.09%
2001 0 0%
2002 2.466.129 100%
2003 2.146.909 -14.87%
2004 6.548.599 67.22%
2005 11.454.773 42.83%
2006 8.509.785 -34.61%
2007 9.625.947 11.6%
2008 5.750.494 -67.39%
2009 9.408.457 38.88%
2010 13.256.606 29.03%
2011 20.032.001 33.82%
2012 17.984.825 -11.38%
2013 21.368.604 15.84%
2014 34.095.039 37.33%
2015 57.791.923 41%
2016 88.712.035 34.85%
2017 98.572.618 10%
2018 95.257.876 -3.48%
2019 88.017.319 -8.23%
2020 94.245.436 6.61%
2021 249.240.324 62.19%
2022 187.650.503 -32.82%
2023 69.012.200 -171.91%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Inovio Pharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1998 0
1999 0 0%
2001 0 0%
2002 3.658.307 100%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 10.005.602 100%
2009 13.669.409 26.8%
2010 12.108.261 -12.89%
2011 0 0%
2012 10.778.359 100%
2013 13.643.074 21%
2014 15.857.688 13.97%
2015 18.063.890 12.21%
2016 23.892.263 24.39%
2017 28.290.369 15.55%
2018 29.315.159 3.5%
2019 27.203.156 -7.76%
2020 37.247.828 26.97%
2021 53.752.353 30.7%
2022 90.185.285 40.4%
2023 40.973.364 -120.11%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Inovio Pharmaceuticals, Inc. EBITDA
Year EBITDA Growth
1998 -6.800.000
1999 -8.371.069 18.77%
2001 0 0%
2002 -5.283.255 100%
2003 -6.048.849 12.66%
2004 -10.937.654 44.7%
2005 -8.046.096 -35.94%
2006 -12.434.551 35.29%
2007 -18.365.359 32.29%
2008 -12.714.443 -44.44%
2009 -11.021.929 -15.36%
2010 -19.588.437 43.73%
2011 -29.491.484 33.58%
2012 -25.783.232 -14.38%
2013 24.187.626 206.6%
2014 -38.274.831 163.19%
2015 -34.542.633 -10.8%
2016 -75.277.527 54.11%
2017 -82.980.679 9.28%
2018 -89.455.166 7.24%
2019 -105.580.479 15.27%
2020 -76.169.571 -38.61%
2021 -293.334.257 74.03%
2022 -268.552.728 -9.23%
2023 -105.899.572 -153.59%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Inovio Pharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
1998 7.100.000
1999 3.619.798 -96.14%
2001 0 0%
2002 189.521 100%
2003 80.529 -135.35%
2004 1.167.099 93.1%
2005 5.467.253 78.65%
2006 3.468.178 -57.64%
2007 4.807.729 27.86%
2008 2.097.632 -129.2%
2009 9.120.111 77%
2010 6.144.705 -48.42%
2011 9.795.257 37.27%
2012 4.118.652 -137.83%
2013 13.467.346 69.42%
2014 10.456.766 -28.79%
2015 40.572.111 74.23%
2016 35.368.361 -14.71%
2017 42.220.086 16.23%
2018 30.481.897 -38.51%
2019 4.111.930 -641.3%
2020 7.411.220 44.52%
2021 1.774.758 -317.59%
2022 10.262.268 82.71%
2023 410.604 -2399.31%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Inovio Pharmaceuticals, Inc. Net Profit
Year Net Profit Growth
1998 -6.600.000
1999 -9.599.942 31.25%
2001 0 0%
2002 -5.964.827 100%
2003 -4.664.907 -27.87%
2004 -10.972.931 57.49%
2005 -15.296.852 28.27%
2006 -12.479.124 -22.58%
2007 -11.204.443 -11.38%
2008 -12.965.622 13.58%
2009 -24.411.485 46.89%
2010 -17.613.796 -38.59%
2011 -15.252.945 -15.48%
2012 -19.668.955 22.45%
2013 -66.028.448 70.21%
2014 -36.121.713 -82.79%
2015 -29.187.606 -23.76%
2016 -73.740.339 60.42%
2017 -88.205.772 16.4%
2018 -96.967.830 9.04%
2019 -119.359.219 18.76%
2020 -166.411.157 28.27%
2021 -303.658.710 45.2%
2022 -279.818.065 -8.52%
2023 -100.014.552 -179.78%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Inovio Pharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1998 -5
1999 -7 16.67%
2001 0 0%
2002 -2 100%
2003 -1 -100%
2004 -2 50%
2005 -3 33.33%
2006 -2 -200%
2007 -1 0%
2008 -1 0%
2009 -1 0%
2010 -1 0%
2011 0 0%
2012 -1 0%
2013 -1 100%
2014 -1 0%
2015 0 0%
2016 -1 100%
2017 -1 0%
2018 -1 0%
2019 -1 0%
2020 -1 0%
2021 -1 0%
2022 -1 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Inovio Pharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
1998 -6.800.000
1999 -9.080.247 25.11%
2000 -8.634.471 -5.16%
2002 -5.368.333 -60.84%
2003 -2.808.033 -91.18%
2004 -6.902.854 59.32%
2005 -12.625.225 45.32%
2006 -8.408.323 -50.15%
2007 -12.159.479 30.85%
2008 -11.710.316 -3.84%
2009 -14.245.127 17.79%
2010 -12.244.157 -16.34%
2011 -19.916.904 38.52%
2012 -22.547.771 11.67%
2013 -15.558.362 -44.92%
2014 -31.203.624 50.14%
2015 -15.220.445 -105.01%
2016 -66.493.522 77.11%
2017 -73.502.823 9.54%
2018 -75.635.178 2.82%
2019 -98.838.062 23.48%
2020 -179.499.711 44.94%
2021 -216.939.531 17.26%
2022 -217.184.574 0.11%
2023 -26.275.785 -726.56%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Inovio Pharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
1998 -6.300.000
1999 -8.790.736 28.33%
2000 -8.370.501 -5.02%
2002 -4.959.618 -68.77%
2003 -2.748.415 -80.45%
2004 -6.800.489 59.59%
2005 -12.338.318 44.88%
2006 -7.043.148 -75.18%
2007 -11.513.749 38.83%
2008 -11.126.518 -3.48%
2009 -14.080.192 20.98%
2010 -11.937.528 -17.95%
2011 -19.755.717 39.57%
2012 -22.306.785 11.44%
2013 -15.381.437 -45.02%
2014 -29.823.644 48.43%
2015 -12.438.901 -139.76%
2016 -62.555.052 80.12%
2017 -63.208.921 1.03%
2018 -73.550.156 14.06%
2019 -97.850.136 24.83%
2020 -177.979.046 45.02%
2021 -215.708.525 17.49%
2022 -216.215.421 0.23%
2023 -26.275.785 -722.87%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Inovio Pharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
1998 500.000
1999 289.511 -72.71%
2000 263.970 -9.68%
2002 408.715 35.41%
2003 59.618 -585.56%
2004 102.365 41.76%
2005 286.907 64.32%
2006 1.365.175 78.98%
2007 645.730 -111.42%
2008 583.798 -10.61%
2009 164.935 -253.96%
2010 306.629 46.21%
2011 161.187 -90.23%
2012 240.986 33.11%
2013 176.925 -36.21%
2014 1.379.980 87.18%
2015 2.781.544 50.39%
2016 3.938.470 29.38%
2017 10.293.902 61.74%
2018 2.085.022 -393.71%
2019 987.926 -111.05%
2020 1.520.665 35.03%
2021 1.231.006 -23.53%
2022 969.153 -27.02%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Inovio Pharmaceuticals, Inc. Equity
Year Equity Growth
1998 8.300.000
1999 11.831.199 29.85%
2001 4.963.105 -138.38%
2002 3.725.370 -33.22%
2003 15.047.635 75.24%
2004 15.549.510 3.23%
2005 23.470.748 33.75%
2006 27.042.551 13.21%
2007 31.034.754 12.86%
2008 19.106.147 -62.43%
2009 61.184.947 68.77%
2010 47.100.911 -29.9%
2011 47.861.662 1.59%
2012 34.857.405 -37.31%
2013 52.902.683 34.11%
2014 111.537.594 52.57%
2015 175.933.053 36.6%
2016 123.378.420 -42.6%
2017 142.488.809 13.41%
2018 87.032.407 -63.72%
2019 5.404.858 -1510.26%
2020 461.140.758 98.83%
2021 399.669.421 -15.38%
2022 222.362.756 -79.74%
2023 117.349.129 -89.49%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Inovio Pharmaceuticals, Inc. Assets
Year Assets Growth
1998 9.800.000
1999 14.012.304 30.06%
2001 6.633.714 -111.23%
2002 5.419.225 -22.41%
2003 16.228.990 66.61%
2004 20.951.502 22.54%
2005 28.978.954 27.7%
2006 35.949.615 19.39%
2007 39.775.021 9.62%
2008 38.987.028 -2.02%
2009 80.628.917 51.65%
2010 56.067.391 -43.81%
2011 61.106.561 8.25%
2012 45.138.754 -35.37%
2013 88.287.207 48.87%
2014 131.785.097 33.01%
2015 213.840.859 38.37%
2016 173.707.166 -23.1%
2017 187.239.270 7.23%
2018 131.113.265 -42.81%
2019 143.951.597 8.92%
2020 539.772.472 73.33%
2021 495.941.493 -8.84%
2022 348.533.302 -42.29%
2023 170.951.423 -103.88%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Inovio Pharmaceuticals, Inc. Liabilities
Year Liabilities Growth
1998 1.500.000
1999 2.181.105 31.23%
2001 1.670.609 -30.56%
2002 1.693.855 1.37%
2003 1.181.355 -43.38%
2004 5.401.992 78.13%
2005 5.508.206 1.93%
2006 8.907.064 38.16%
2007 8.740.267 -1.91%
2008 19.880.881 56.04%
2009 19.443.970 -2.25%
2010 8.966.480 -116.85%
2011 13.244.899 32.3%
2012 10.281.349 -28.82%
2013 35.384.524 70.94%
2014 20.247.503 -74.76%
2015 37.907.806 46.59%
2016 50.328.746 24.68%
2017 44.750.461 -12.47%
2018 44.080.858 -1.52%
2019 138.546.739 68.18%
2020 78.631.714 -76.2%
2021 96.272.072 18.32%
2022 126.170.546 23.7%
2023 53.602.294 -135.38%

Inovio Pharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
-0.51
Price to Earning Ratio
-1.18x
Price To Sales Ratio
16.55x
POCF Ratio
-1.28
PFCF Ratio
-0.11
Price to Book Ratio
1.36
EV to Sales
35.66
EV Over EBITDA
-0.23
EV to Operating CashFlow
-0.24
EV to FreeCashFlow
-0.24
Earnings Yield
-0.85
FreeCashFlow Yield
-9.05
Market Cap
0,01 Bil.
Enterprise Value
0,03 Bil.
Graham Number
2.26
Graham NetNet
0.36

Income Statement Metrics

Net Income per Share
-0.51
Income Quality
0.92
ROE
-0.87
Return On Assets
-0.79
Return On Capital Employed
-1.12
Net Income per EBT
1
EBT Per Ebit
0.94
Ebit per Revenue
-173
Effective Tax Rate
0.03

Margins

Sales, General, & Administrative to Revenue
57.19
Research & Developement to Revenue
104.18
Stock Based Compensation to Revenue
13.31
Gross Profit Margin
1
Operating Profit Margin
-173
Pretax Profit Margin
-162.4
Net Profit Margin
-162.4

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.47
Free CashFlow per Share
-0.47
Capex to Operating CashFlow
0
Capex to Revenue
-0.39
Capex to Depreciation
-0.09
Return on Invested Capital
-0.87
Return on Tangible Assets
-0.79
Days Sales Outstanding
1055.16
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0.35
Payables Turnover
0
Inventory Turnover
0
Capex per Share
-0

Balance Sheet

Cash per Share
0,55
Book Value per Share
0,44
Tangible Book Value per Share
0.44
Shareholders Equity per Share
0.44
Interest Debt per Share
0.12
Debt to Equity
0.26
Debt to Assets
0.18
Net Debt to EBITDA
-0.13
Current Ratio
3.6
Tangible Asset Value
0,12 Bil.
Net Current Asset Value
0,10 Bil.
Invested Capital
0.26
Working Capital
0,11 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
5254269
Debt to Market Cap
2.19

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Inovio Pharmaceuticals, Inc. Dividends
Year Dividends Growth

Inovio Pharmaceuticals, Inc. Profile

About Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

CEO
Dr. Jacqueline E. Shea Ph.D.
Employee
184
Address
660 West Germantown Pike
Plymouth Meeting, 19462

Inovio Pharmaceuticals, Inc. Executives & BODs

Inovio Pharmaceuticals, Inc. Executives & BODs
# Name Age
1 Mr. Daniel Jordan
Senior Vice President of Device Manufacturing Operations
70
2 Dr. Laurent M. Humeau Ph.D.
Chief Scientific Officer
70
3 Mr. Stephen Kemmerrer M.B.A., P.E.
Senior Vice President of Engineering Development
70
4 Mr. Shawn D. Bridy M.A., M.B.A., MA, MBA
Senior Vice President of Bus. Devel.
70
5 Mr. Shawn D. Bridy M.A., M.B.A.
Senior Vice President of Business Development
70
6 Ms. Asli Gevgilili
Chief HR Officer
70
7 Mr. E. J. Brandreth MBA
Senior Vice President of Quality Assurance
70
8 Ben Matone
Director of Investor Relations
70
9 Dr. Jacqueline E. Shea Ph.D.
Chief Executive Officer, President & Director
70
10 Mr. Peter D. Kies
Chief Financial Officer
70
11 Thomas Hong
Manager of Investor Relations
70
12 Mr. Robert J. Juba Jr.
Senior Vice President of Biological Manufacturing & Clinical Supply Management
70
13 Dr. Jeffrey Skolnik
Senior Vice President of Clinical Development
70

Inovio Pharmaceuticals, Inc. Competitors

Novavax, Inc. Logo
Novavax, Inc.

NVV1.F

(2.5)
Moderna, Inc. Logo
Moderna, Inc.

0QF.F

(1.2)